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BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in
neuroblastoma without MYCN amplification (MNA) was tested.
METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/or chromosome 17q
gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were
considered as having no segmental chromosomal alterations.
RESULTS: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397
cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type
was more frequent in patients 418 months and in stage 4 disease (Po0.0001). In univariate analysis, 11q deletion, 17q gain and a
segmental genomic type were associated with a poorer event-free survival (EFS) (Po0.0001, P¼0.0002 and Po0.0001,
respectively). In multivariate analysis modelling EFS, the parameters age, stage and a segmental genomic type were retained in the
model, whereas the individual genetic markers were not (Po0.0001 and RR¼2.56; P¼0.0002 and RR¼1.8; P¼0.01 and RR¼1.7,
respectively).
CONCLUSION: A segmental genomic profile, rather than the single genetic markers, adds prognostic information to the clinical markers
age and stage in neuroblastoma patients without MNA, underlining the importance of pangenomic studies.
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Neuroblastoma (NB), the most frequent extracranial solid tumour
of childhood, is characterised by a wide variability of its clinical
course. Clinical markers, such as stage and age at diagnosis, are
insufficient to precisely predict outcome in all patients. This has
led to the search for additional markers that might enable a more
robust prognostic classification of NB (Maris, 2010). A large
number of recurrent genetic alterations have been identified in NB.
Amplification of the MYCN oncogene (MNA) is observed in
approximately 20% of cases and is clearly associated with a poor
outcome (Seeger et al, 1985). Variations of ploidy have also
been described in NB, with near-triploidy associated with
an excellent outcome, and diploidy/tetraploidy correlating with a
poorer outcome (Look et al, 1991). Finally, a number of segmental
chromosomal alterations have been reported, including deletions
of chromosomes 1p, 3p, 4p and 11q, thought to harbour
tumour suppressor genes, and gains of chromosomes 1q, 2p
and 17q, harbouring putative oncogenes. A large number
of these segmental alterations have been shown to be of
prognostic impact in univariate analyses (Maris et al, 1995;
Caron et al, 1996; Schleiermacher et al, 1996; Bown et al, 1999;
Spitz et al, 2003, 2004; Attiyeh et al, 2005; Pezzolo et al, 2009;
Jeison et al, 2010).
The development of high-throughput techniques such as
chromosomal or array CGH has enabled the analysis of these
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sparameters in a multivariate setting. It has been shown that the
different genetic alterations combine to define distinct genetic
subtypes of NB associated with specific clinical and prognostic
characteristics (Lastowska et al, 2001; Vandesompele et al, 2005;
Maris et al, 2007). Indeed, a genomic profile characterised by the
presence of any of the segmental alterations typically observed in
NB is strongly associated with a higher risk of relapse as well as
a poorer outcome as compared with patients having numerical
alterations only (Schleiermacher et al, 2007). Such a genomic
profile is also associated with a higher risk of relapse, and a higher
risk of metastatic relapse, not only in the overall population but
also among patients with localised disease. Furthermore, patients
whose tumours have genomic profiles harbouring both numerical
and segmental alterations share the poor outcome of those
with segmental alterations only (Janoueix-Lerosey et al, 2009).
In multivariate analysis, taking into account clinical markers,
single genetic markers as well as the genomic profile, the latter is
the strongest independent prognostic factor. Segmental chromo-
somal changes are associated with a higher risk of relapse in
infants with localised unresectable or metastatic NB without MNA
(Schleiermacher et al, 2011). Recent studies also indicate that NB
progression is associated with an accumulation of segmental
chromosomal changes, and that a higher number of segmental
changes is observed in tumours from children with advanced age
(Caren et al, 2010; Schleiermacher et al, 2010).
To develop an improved pre-treatment risk assessment for NB
patients, the INRG (International Neuroblastoma Risk Group) task
force created a database uniting clinical, histological, radiological
and biological data sets from 8800 international NB patients.
Analysis of these data led to the development of a pre-treatment
INRG risk classification that includes the genetic parameters
MYCN status, 11q status and ploidy (Ambros et al, 2009; Cohn
et al, 2009; Monclair et al, 2009). However, the prognostic value
of individual segmental chromosomal alterations was evaluated in
this analysis, rather than genomic types. We have now analysed the
INRG dataset to determine if the analysis of recurrent genetic
alterations observed in NB allows the classification of NB into
distinct groups according to the genomic profile in this large
retrospective cohort (INRG database). We furthermore sought to
determine if a segmental genomic profile is of prognostic impact in
this cohort, especially in patients without MNA.
MATERIALS AND METHODS
The INRG dataset comprises data for 8800 international patients
(Cohn et al, 2009). The following data were retrieved from the
INRG database: clinical data (date of birth, sex; date of diagnosis,
tumour stage, relapse or progression (if yes: date); date of
last follow-up and status at last follow-up); biological data (LDH,
urinary catecholamines at diagnosis); and tumour characteristics
(MYCN status, ploidy, chromosome 1p status, chromosome
11q status, chromosome 17q status). These genetic markers were
determined using different techniques, including fluorescent
in situ hybridisation (FISH) and loss of heterozygosity (LOH)
analysis (Ambros et al, 2009; Cohn et al, 2009). Subsequently,
unbalanced 11q LOH and 11q aberrations data were combined
into a single variable: ‘11q aberration’. Similarly, 1p LOH and 1p
aberrations were combined into the variable ‘1p aberration’.
A segmental chromosomal alteration was defined as either the
presence of an aberration of the respective chromosome arm,
as determined by FISH, or in the case of deletion or imbalance, as
determined by LOH. The presence of any segmental chromosomal
alteration in a tumour (chromosome 1p deletion and/or 11q
deletion and/or chromosome 17q gain) was taken into account to
define a segmental genomic profile, whereas those tumours with a
confirmed unaltered status for all three chromosome arms were
considered as having no segmental changes. Tumours with a
DNA index of p1 were termed diploid, whereas tumours with a
DNA index of 41 were termed hyperdiploid.
Correlation between clinical and molecular data was assessed by
using the chi-square test, or Fisher’s exact test when indicated.
Event-free survival (EFS) and overall survival (OS) were estimated
with the Kaplan–Meier method and compared by the log-rank test
with a P-value of less than 0.05 considered to be significant. Event-
free survival was calculated from diagnosis until the date of last
follow-up or event (first occurrence of relapse, progression,
secondary malignancy, or death from any cause). Overall survival
was calculated from diagnosis to the last follow-up or death from
any cause. Multivariate analysis was conducted on EFS and OS,
using a Cox regression model, with a backward procedure.
RESULTS
Among the 8800 patients in the INRG database, MYCN status
was known in 7102 cases, with MNA present in 1155 cases.
Chromosome 1p status was known in 2152 patients with 493
presenting with 1p deletion, chromosome 11q status was known in
1064 patients with 220 having 11q deletion and chromosome
17q status was known in 362 cases with 175 having 17q gain.
For 342 cases, the status at all three chromosome arms 1p, 11q and
17q was known.
A genomic type could be attributed to 814 patients (257 with
MNA, 505 without MNA and 52 with unknown MYCN status).
In 119 cases, all three chromosome arms 1p, 11q and 17q had a
normal status, and these cases were considered as having no
segmental chromosome alterations. In a further 695 cases, a
segmental alteration of either chromosome 1p and/or 11q and/or
17q was observed, and these cases were termed segmental genomic
type. A strong association between a segmental genomic type and
MNA was observed (Po0.0001). Indeed, in only six tumours with
MNA a normal status for chromosome 1p, 11q and 17q was
observed, four of whom have relapsed.
As the prognostic impact of MNA has been widely documented,
we then focused our analysis on patients without MNA. For 505
patients without MNA for whom a genomic type could be
determined, the medium follow-up was 63 months (range 0–167
months), with 207 events and 129 deaths having occurred. Among
these 505 patients, 108 cases had no segmental chromosomal
alterations, whereas in 397 other cases a segmental genomic type
was observed, with the chromosome status known at all three
chromosomal loci in 221 cases (Figure 1). A segmental genomic
type was observed more frequently in stage 4 disease and in
children aged 418 months (Table 1).
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Figure 1 Frequency of detection the genetic alterations chromsome 1p
deletion, chromosome 11q deletion and chromosome 17q gain among 397
patients without MYCN amplification harbouring at least one genetic
alteration in the INRG database.
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sAmong these 505 patients without MNA, for whom a genomic
type could be attributed, diploidy, chromosome 11q deletion and
chromosome 17q gain were significantly associated with poorer
EFS and OS in univariate survival analysis, as was a segmental
genomic type (Table 2, Figure 2). In a multivariate analysis
modelling for EFS, the parameters age 418 months, stage 4 disease
and a segmental genomic type were associated with a higher risk of
relapse, whereas the individual genetic markers and ploidy were
not (Po0.0001 and RR¼2.6; P¼0.0002 and RR¼1.8; P¼0.01
and RR¼1.7, respectively, Table 3). Likewise, in a multivariate
analysis modelling for OS, the same parameters age, stage and a
segmental genomic type were retained in the model (Po0.0001
and RR¼4.6; Po0.0001 and RR¼3.1; P¼0.05 and RR¼1.8,
respectively). In particular, a segmental genomic type was
associated with a significantly poorer EFS in the 86 patients older
than 18 months with non-stage 4 disease (Po0.02).
DISCUSSION
In NB, a number of genetic aberrations have been identified that
are strongly associated with outcome, including deletions of
chromosomes 1p, 3p, 4p and 11q, and gains of chromosomes 1q
and 17q (Maris et al, 1995; Caron et al, 1996; Schleiermacher et al,
1996; Bown et al, 1999; Spitz et al, 2003; Attiyeh et al, 2005; Pezzolo
et al, 2009). Gains of chromosome 2p, harbouring the MYCN gene,
have also been shown to be associated with a poor outcome
(Spitz et al, 2004; Jeison et al, 2010). The extensive INRG dataset
includes information on ploidy, chromosome 1p, 11q and 17q
status, as well as on MYCN status, distinguishing MNA from
Table 1 Frequency of a segmental genomic type in neuroblastoma
without MYCN amplification
No segmental
alterations
a
‘Segmental’
type
b Chi-square
Stage
Localised (n¼236) 67 169
Stage 4 (n¼234) 27 207 Po0.0001
Stage 4s (n¼35) 14 21
Age
o18 months (n¼240) 73 167 Po0.0001
418 months (n¼265) 35 230
Ploidy
Diploid (n¼76) 1 75
Hyperdiploid (n¼43) 1 42 NS (Fischer test)
Missing data (n¼386)
Abbreviation: NS¼not significant. For the definition of no segmental alterations, all
three markers have to have a normal status, leading to the determination of an
altogether lower number of ‘no segmental alteration’ cases (see text).
aDefined as a
normal status at all three chromosome arms 1p, 11q and 17q.
bDefined as the
presence of a segmental chromosomal alteration of either chromosome 1p and/or
11q and/or 17q.
Table 2 Univariate analysis of EFS and OS according to genetic markers
in 505 patients without MYCN amplification for whom a genomic type
could be attributed
Parameter
4-year EFS
(%±s.d.)
Log
rank (P)
4-year OS
(%±s.d.)
Log
rank (P)
Ploidy
Hyperdiploid (n¼43) 65±6.1 0.05 74±6.6 0.0025
Diploid (n¼76) 45±8.9 44±12
1p status
Normal (n¼290) 63±2.9 0.06 79±2.6 0.11
Deletion (n¼205) 55±3.7 72±3.3
11q status
Normal (n¼207) 75±3 o0.0001 88±2.4 o0.0001
Deletion (n¼197) 42±3.8 65±3.9
17q status
Normal (n¼146) 75±3.6 0.0002 86±2.9 0.0001
Gain (n¼118) 49±4.7 72±4.3
No segmental
alterations (n¼108)
79±3.9 o0.0001 88±3.2 0.0001
‘Segmental’ type (n¼397) 53±2.7 71±2.5
Abbreviations: EFS¼event-free survival; OS¼overall survival.
Event-free survival
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‘Segmental’ type (n=397)
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Figure 2 Event-free and overall survival in 505 patients without
MYCN amplification for whom a genomic type could be attributed.
‘Segmental’ genomic type: presence of either chromosome 1p deletion
and/or chromosome 11q deletion and/or chromosome 17q gain.
No segmental changes: no alteration for all three genetic markers.
Table 3 Multivariate analysis modelling EFS in a backward model
RR CI P-value
Age 418 months 2.6 1.8–3.6 o0.0001
Stage 4 1.8 1.3–2.5 0.0002
‘Segmental’ type 1.7 1.1–2.7 0.01
The individual genetic markers 1p deletion, 11q deletion and 17q gain were not
retained in the model.
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number variations including 2p gain is given. The major
unfavourable prognostic impact of MNA has led to the inclusion
of the MYCN status in the INRG pre-treatment risk classification
system. The other genetic parameters retained in the INRG
pre-treatment classification scheme are 11q status and ploidy,
with 11q aberration distinguishing stage L2 or MS patients with a
worse outcome and diploidy identifying stage M infants with a
poorer outcome (Bagatell et al, 2009; Cohn et al, 2009; Monclair
et al, 2009).
Several different techniques, including FISH and LOH studies,
were used for the identification of structural aberrations. As the
INRG retrospective data does not include higher throughput data
such as pangenomic data obtained by multiplex ligation-
dependent probe amplification (MLPA), array-CGH or SNP-arrays,
a complete genetic dataset was available for only a few patients.
However, the information available in the INRG database can be
used to confirm the absence of segmental chromosome alterations
at chromosomes 1p, 11q and 17q, thus identifying a non-segmental
genomic type. Recent analyses show that 17q gain, 1p deletion
and 11q deletion are the most frequent segmental chromosome
alterations in tumours without MNA (Tomioka et al, 2008;
Janoueix-Lerosey et al, 2009; Coco et al, 2012). Taking into
account segmental alterations of any of the three chromosome
arms 1p/11q/17q will thus identify the majority of all tumours with
a segmental genomic type. Indeed, in previous studies, 155 out of
175 cases with a segmental genomic type without MNA, and 43
out of 48 infants with a segmental genomic type without MNA,
had alterations of either chromosome 1p, and/or 11q, and/or 17q
(Janoueix-Lerosey et al, 2009; Schleiermacher et al, 2011). We now
show that in the INRG database, a segmental genomic type defined
by the presence of any segmental chromosome alteration, at the
three evaluated chromosome arms, is associated with clinical
parameters predicting poor outcome, and in patients without
MNA, a segmental genomic type is associated with a higher risk
of relapse and a poorer outcome than in patients with a non-
segmental genomic type. Indeed, a genomic profile characterised
by any of the three segmental alterations adds prognostic
information to the parameters ‘age’ and ‘stage’ rather than the
individual genetic markers.
The more stringent definition of the absence of segmental
chromosome alterations, for which the status at all three
chromosome arms had to be known, when compared with the
definition of a segmental type, for which an alteration of any of
the chromosome arms was sufficient, might lead to an under-
representation of non-segmental cases. However, survival analyses
revealed comparable results when analysing the population of
patients with all genetic markers known.
Several recent studies indicate that the presence of segmental
chromosomal alterations, rather than individual genetic markers,
may provide prognostic information in patients with MYCN non-
amplified tumours (Tomioka et al, 2008; Janoueix-Lerosey et al,
2009; Caren et al, 2010; Schleiermacher et al, 2011). According to
one hypothesis, the genomic type is thought to reflect an
underlying genomic abnormality. In tumours with numerical
aberrations, an abnormality in the mitotic segregation of the
chromosomes may exist. On the other hand, the segmental
chromosomal alterations in high- and intermediate-risk tumours
are most frequently due to unbalanced chromosomal transloca-
tions, which in turn are thought to arise from improperly repaired
DNA double-strand breaks, suggesting that a DNA maintenance or
repair pathway is most likely impaired. Thus, the specific genetic
markers analysed here could serve as surrogate markers for
an underlying abnormality that will confer additional selective
advantage (Schleiermacher et al, 2010).
The wide availability and cost reduction of multi-locus
techniques such as MLPA and pangenomic assays such as array-
CGH or SNP-arrays strongly favour the prospective analysis of all
neuroblastic tumours (Ambros et al, 2009). Further, our data
strongly support the idea that pangenomic analysis should be
performed for all NBs, and that a genomic profile defined by the
presence or absence of specific segmental chromosome alterations
will be clinically useful for risk stratification particularly in NBs
without MNA.
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